Treatment of type I diabetes
US7517529B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 4, 2005 |
| Grant date | Apr 14, 2009 |
| Priority date | — |
| Expiry date | Jun 6, 2026 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to the field of immunology, more specifically to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease and other inflammatory diseases. The invention in particular relates to the systemic treatment of inflammatory disease by oral or mucosal administration of a pharmaceutical composition with a gene-regulatory peptide. The invention provides a pharmaceutical composition in a form for mucosal application for the treatment of a subject suffering from disease, the pharmaceutical composition comprising a pharmacologically effective amount of a gene-regulatory peptide or a functional analogue thereof together with a pharmaceutically acceptable diluent.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.